University of California - San Diego is an educational institution that offers undergraduate and graduate courses in Aerospace Engineering, Anthropology, Bioengineering, Computer Science & Engineering, Economics, History, Literature, and Music. The University has six colleges that include Thurgood Marshall, John Muir, Revelle, Roosevelt, Sixth, and Warren College. University of California - San Diego has endowment assets of $274 millions.
9500 Gilman Drive
La Jolla, CA 92093
Founded in 2007
Retrosense Therapeutics Secures Exclusive Worldwide Rights to ReaChR Optogene from the University of California San Diego
Sep 1 16
RetroSense Therapeutics LLC announced the Company has signed a worldwide license with the University of California San Diego to secure exclusive rights to develop red activatable channelrhodopsin (ReaChR), a next-generation optogene developed by the late Nobel Laureate Roger Y. Tsien, Ph.D. Financial terms were not disclosed. This important product builds on the Company’s optogenetics development programs which include pioneering, proprietary research conducted by Dr. Zhuo-Hua Pan and others at Wayne State University’s Kresge Eye Institute and Department of Anatomy and Cell Biology, and Dr. Richard Masland’s team at Massachusetts Eye and Ear Infirmary.
Cleveland Clinic, UCLA and University of California San Diego Collaboration Demonstrates Potential Treatment Enhancement for Advanced Brain Cancer
Jun 1 16
Doctors at Cleveland Clinic, UCLA, University of California San Diego School of Medicine and additional institutions have achieved a milestone in development of a treatment for people with recurrent glioblastoma, the most common and aggressive form of brain cancer, by successfully demonstrating a modified virus that can extend the lives of patients with recurrent glioblastoma. Glioblastomas are the most deadly of all brain cancers. If the tumor recurs following chemotherapy and radiation, there are very few treatment options left, and patients have only months to live. In a phase I multi-center clinical trial, Cloughesy and Vogelbaum afound that, of the 43 participants who were given the investigational treatment Toca 511 and Toca FC, overall survival increased to 13.6 months compared to 7.1 months for an external control. For some patients, survival was extended to more than two years with few side effects. In 2016, the total number of newly diagnosed high-grade glioblastoma will be about 160,000 worldwide, including 14,000 in the United States. The new findings were led by Drs. Timothy Cloughesy, a member of the UCLA Jonsson Comprehensive Cancer Center and director of the UCLA neuro-oncology program, and Michael A. Vogelbaum, professor of neurosurgery and associate director of the brain tumor neuro-oncology center at the Cleveland Clinic. Their work is the first publication of clinical data involving this new type of modified virus known as a retroviral replicating vector (RRV). RRVs can deliver a gene with a specific function to a cancer cell, and insert it, thereby debilitating the cell. The use of RRVs shows tremendous promise in the development of innovative new therapies for all types of brain cancer. During the first step of treatment the patient is given an injection of Toca 511, which is a modified virus that selectively infects actively dividing cancer cells and delivers a gene for an enzyme called cytosine deaminase (CD) to the cancer cells. As it spreads through the tumor, Toca 511 programs the cancer cells to make (CD). Once they do, the cancer cells are then ready for the second step of the treatment. Next, the patient is prescribed oral cycles of Toca FC, an antifungal drug, for seven days, every four to eight weeks. The genetic changes created by Toca 511 allows infected cancer cells to convert Toca FC into the FDA-approved anticancer drug, 5-fluorouracil (5-FU). As a result, infected cancer cells and immunosuppressive cells are selectively killed, subsequently activating the immune system to recognize and kill cancer cells, while leaving healthy cells unharmed. In other words, the therapies work together to attack brain cancer cells from the inside. An estimated 40% of study participants who received higher doses of the combo treatment during the phase I clinical trial were still living after two years. The researchers also noted that some study participants had partial or complete shrinkage of their tumor. Importantly, Toca 511 & Toca FC demonstrated a favorable safety and tolerability profile.
University of California - San Diego Presents at BIO-Europe Spring 2016, Apr-05-2016 03:45 PM
Apr 2 16
University of California - San Diego Presents at BIO-Europe Spring 2016, Apr-05-2016 03:45 PM. Venue: Kistamässan Convention Center, Stockholm, Sweden. Speakers: Mary Lindenstein Walshok, Associate Vice Chancellor for Public Programs and Dean of Extension.